Zeo ScientifiX, Inc.

We are a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics for degenerative diseases and regenerative medicine. We have a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes, and Wharton's Jelly matrix. Our principal product is Zofin™, which is derived from amniotic fluid and manufactured to retain naturally occurring extracellular vesicles, proteins, and cell-secreted nanoparticles. We also manufacture Patient Pure X™ ("PPX™"), a proprietary autologous biologic containing a nanoparticle fraction precipitated from a patient's own peripheral blood. All of our products are manufactured in FDA-registered, cGMP-compliant laboratory facilities. Our portfolio of products ("RAAM Products") and related services are primarily used in the healthcare industry and administered through doctors and clinics ("Providers"). The state of Florida enacted a new "stem cell therapy" law, effective July 1, 2025 ("SB 1768"). This legislation authorizes licensed physicians to administer non-FDA-approved stem cell and other human tissue-derived therapies for orthopedic, wound care, and pain management indications. It mandates compliance with cGMP and prohibits the use of stem cells derived from aborted fetuses, promoting ethically sourced materials such as adult stem cells and umbilical cord blood. SB 1768 also requires informed patient consent and disclosure that treatments are not FDA-approved. We have begun to pursue clinical research and commercial sales strategies that comply with SB 1768.